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RESUMO
O leiomiossarcoma da veia cava inferior é um tumor raro, constituindo apenas 0,5% dos sarcomas de tecidos moles. À semelhança 
de outros leiomiossarcomas de origem vascular, estão associados a um mau prognóstico, sendo a ressecção com margens livres 
de tumor o único tratamento potencialmente curativo. Apresentamos um caso de uma doente de 46 anos com um leiomiossarcoma 
metastizado, refratário a antraciclinas e ifosfamida, e com resposta completa e prolongada sob trabectedina. Após progressão, a 
doente iniciou terapêutica de terceira linha com pazopanib. Será feita uma breve revisão da literatura. Este caso suporta a eficácia de 
uma terapêutica recente, demonstrando uma sobrevivência livre de progressão atípica num leiomiossarcoma metastático e refratário.
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INTRODUCTION
 The soft tissue sarcomas (STM) are a heterogeneous 
group of rare tumors that develop from the mesenchymal 
stem cells which can differentiate in several cell lines (mus-
cle, adipose, and connective tissue).1 
 The leiomyosarcoma is the second most frequent 
histological subtype of STM (28%) and the most common 
primary tumor of the inferior vena cava. However, the 
inferior vena cava leiomyosarcoma (IVCL) represents only 
0.5% of STM, with approximately 300 cases described in 
literature.2 
 The clinical presentation is typically insidious and 
nonspecific, which often leads to diagnosis in advanced 
stage. The most common presenting symptom is pain in the 
right flank.3 
 Surgical resection, eventualy in combination with 
neoadjuvant and/or adjuvant treatment, is the only 
potentially curative therapy. However, advanced and 
metastatic STS have a poor prognosis.1 Effective anti-
tumoral agents in the treatment of patients with metastatic 
STS are limited, especially when there is no response to 
conventional therapy with anthracyclines and ifosfamide.4 
 Trabectedin is an anti-tumoral agent originally extracted 
from the ascidian Ecteinascidia turbinata and currently 
obtained by chemical synthesis. Approved in 2007, 
trabectedin is indicated for the treatment of patients with 
advanced STM refractory to therapy with anthracyclines 
and ifosfamide, or if treatment with these drugs is not 
indicated.5 Pazopanib, a multitargeted tyrosine kinase 
inhibitor, was also recently approved for nonadipocytic soft 
tissue sarcomas refractory to chemotherapy.6 
 We report the case of a patient with IVCL treated with 
multiple anti-tumoral agents, achieving a complete and 
prolonged remission with trabectedin.
CASE REPORT
 46-year old female, admitted in December 2010 with 
nonspecific abdominal pain. No relevant personal history 
and a physical exam without findings. An abdominal 
computerized tomography (CT) showed a large, well 
defined retroperitoneal mass, with heterogeneous contrast 
uptake and slightly lobulated contours in contact with the 
duodenum, kidney, right ureter, aorta and inferior vena cava 
(IVC). An exploratory laparotomy was performed, with a 
bloc ressection of the tumor mass without intraoperative 
complications. Histological and immunohistochemical 
analyses revealed a grade 3 leiomyosarcoma arising from 
the IVC, with positive margins.
 Re-staging postoperative CT revealed hepatic and 
pulmonary metastasis. She started in 30/05/11 palliative 
combination chemotherapy with doxorubicin, ifosfamide, 
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cisplatin, a total of six cycles every three weeks. The 
patient achieved complete remission, both imagiologic and 
metabolic, with grade 3 hematologic toxicity. After thirteen 
months there was disease progression, with oligometastatic 
but unressectable disease, including one lung metastases 
and three liver metastases. Given the excellent response 
and progression-free interval, she was re-challenged 
with the same chemotherapy regimen. Considering the 
limits imposed by the cumulative dose of doxorubicin, the 
liposomal formulation was prefered in attempt to reduce 
cardiotoxicity. Cardiac evaluation regularly perfomed 
showed stable left ventricular function. The patient had 
renal toxicity at cycle 2, with acute proximal tubular necrosis 
induced by ifosfamide - iatrogenic Fanconi syndrome. 
 With a second hepatic and pulmonar relapse (Fig. 1) and 
without possibility to continue chemotherapy with the same 
agents, the patient started in April 2013 second line palliative 
chemotherapy with trabectedin at the recommended dose 
of 1.5 mg/m2 administered as intravenous infusion over 
24 hours, every 3 weeks. Considering the toxicity profile 
of trabectedin and the previous hematologic toxicity she 
recieved prophylactic granulocyt-colony stimulating factor 
throughout the treatment. Evaluation was perfomed every 
3 cycles, with partial response at cycle 3 and complete 
response (imagiologic and metabolic) at cycle 7, August 
2013. (Fig. 2). 
 The patient remained asymptomatic, only with transitory 
grade 1 fatigue and transaminases elevation and without 
evidence of disease until completing twenty one cycles of 
trabectedin (September 2014), time of second progression 
(Fig. 3) with three hepatic lesions in the segment VII (7 
mm), V segment (10 mm) and VI segment (10 mm). 
 The patient started third line treatment with Pazopanib 
with stable disease on the first response assessment.
DISCUSSION
 Inoperable STS present mostly a poor prognosis. 
The median survival of these patients is 8-13 months 
with anthracyclines and ifosfamide based-chemotherapy. 
Survival after progression with this therapy is 6 months.7 
 The identification of therapeutic alternative for the 
treatment of patients with refractory STM is essential. 
Trabectedin was originally isolated from the Caribbean sea 
sponge Ecteinascidia turbinate. It covalently binds to the 
minor groove of DNA to cause drug-induced DNA damage, 
which results in perturbations in the cell cycle and induction 
of apoptosis.8 
 The efficacy and safety of trabectedin in the treatment 
of STS was evaluated in a clinical trial with locally advanced 
and metastatic liposarcoma and leiomyosarcoma refractory 
to treatment with anthracyclines and ifosfamide. This trial 
showed a progression-free survival (PFS) of 3.3 months and 
an overall survival of 13.9 months in the group submitted 
 
Figure 1 - Positron emission tomography - computed tomography 
(PET/CT) showing the second hepatic relapse after chemothera-
py re-challenge, interrupted after a grade 4 renal toxicity (Fanconi 
syndrome)
 
Figure 2 - Computed tomography (CT) without hepatic nodules af-
ter cycle 7 of trabectedin, when the patient achieved a complete 
response, both hepatic and pulmonary
 
Figure 3 - Computed tomography (CT) showing hepatic recurrence 
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to trabectedin, 1.5 mg/m2 as an intervenous infusion for 24 
hours every 3 weeks.7 
 It presents as a valid therapeutic option for patients with 
STS refractory to anthracyclines and ifosfamide, specifically 
in IVCL subtype.7 
 The most common adverse reactions described in the 
literature include neutropenia, nausea, vomiting, elevation 
of transaminases, anemia, fatigue, thrombocytopenia, 
anorexia and diarrhoea, mostly transitory and reversible.9 
In clinical trials there were no cumulative toxicity in patients 
treated with multiple cycles. Therefore there isn’t an 
established limit to the number of treatment cycles with 
trabectedin and could be offered as long as clinical benefit is 
observed. A recent randomized phase II trial recommended 
maintenance treatment beyond six trabectedin cycles until 
disease progression, with good tolerability.10 
 More recently, a phase III trial comparing trabectedin 
to dacarbazine in metastatic lipossarcoma and leio-
myossarcoma after chemotherapy, also favors trabectedin 
in terms of PFS.9 Another treatment option in this setting, 
pazopanib is a synthetic indazolylpyrimidine that functions 
as a multitargeted tyrosine kinase inhibitor (TKI) with a high 
affinity for vascular endothelial growth factor receptors and 
a low affinity for platelet-derived growth factor receptors, 
fibroblast growth factor receptors, and c-Kit.11 The PALETTE 
trial, the phase III trial that gave approval of pazopanib (800 
mg orally once daily) for metastatic STS after failure with 
chemotherapy, reported a significantly prolonged PFS of 
4.6 months compared to 1.6 months for placebo. The most 
common adverse effects were fadigue, diarrhoea, nausea, 
weight loss and hypertension.6 
 An active area of research in STS is the use of novel 
combinations of agents, such as chemotherapy combined 
with multi-targeted agents. 
 The potential of immune check point inhibitors is being 
explored in advanced STS and is hoped to further expand 
our treatment armamentarium.12 The patient had a very 
favorable tolerability, with grade 1 fatigue and transminases 
elevation, in agreement with the toxicity profile reported in 
clinical trials. Treatment with trabectedin was maintained for 
twenty one cycles, always with clear clinical benefit and an 
aproximately 17 months PFS with complete response. 
 The third line therapy with pazopanib was also well 
tolerated, with stable disease at first response evaluation. 
We intend to show a case of exceptional rarity and a 
clinical response that, although uncommon, reinforces the 
role of trabectedin in the treatment of STS advanced and 
refractory to anthracyclines and ifosfamide, specifically in 
the treatment of histological subtype IVCL.
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